# Trade Mark Journal No.2026/013 27 March 2026

## WO0000001892409 (42,44)

Office of origin: United States of America

Date of International Registration:22 October 2025
Date of designation in the UK: 22 October 2025

International priority date claimed: 24 April 2025 (United States of America) (99153728)

Class 42
  Medical and scientific research in the field of oncology; providing medical and scientific research information in the field of oncology; medical and scientific research, namely, whole genome and whole transcriptome sequencing assays for biomarker detection and analysis in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies.
Class 44
  Medical testing for diagnostic, prognostic, or treatment purposes; medical testing, namely, whole genome and whole transcriptome sequencing assays for biomarker detection in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies.

Caris MPI, Inc.

Representative: Anne Fleeson Womble Bond Dickinson (US) LLP, One West Fourth Street, Winston-Salem NC 27101, UNITED STATES OF AMERICA